Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience
September 17, 2024
Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.
- Buyers
- Bain Capital Life Sciences, Vivo Capital
- Targets
- Serán Bioscience
- Industry
- Pharmaceuticals
- Location
- Oregon, United States
- Transaction Type
- Growth capital
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.